论文部分内容阅读
目的观察重组基因干扰素α-1b与胸腺肽治疗慢性乙型病毒性肝炎(CHB)的临床疗效。方法选择门诊及住院的慢性乙型病毒性肝炎患者140例,其中干扰素治疗组90例;保肝治疗组60例。观察2组患者的肝功能。结果干扰素联合胸腺肽治疗组的ALT复常率和HbeAg阴转率均明显高于保肝治疗组,差异均有统计学意义(P<0.01)。结论干扰素α-1b与胸腺肽是目前治疗慢性乙型病毒性肝炎较为有效的药物。
Objective To observe the clinical efficacy of recombinant interferon α-1b and thymosin in the treatment of chronic hepatitis B (CHB). Methods Outpatients and hospitalized patients with chronic hepatitis B 140 cases, of which 90 cases of interferon treatment group; Liver protection group of 60 cases. The liver function of the two groups was observed. Results The ALT normalization rate and HbeAg negative conversion rate of interferon combined with thymosin treatment group were significantly higher than those of liver protection group (all P <0.01). Conclusion Interferon α-1b and thymosin are the most effective drugs for the treatment of chronic hepatitis B at present.